These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30981)

  • 21. Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices.
    Scimonelli T; Celis ME
    Peptides; 1982; 3(6):885-9. PubMed ID: 6132363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide.
    Baures PW; Ojala WH; Costain WJ; Ott MC; Pradhan A; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1997 Oct; 40(22):3594-600. PubMed ID: 9357526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the DOPA-potentiation test.
    Spirtes MA; Plotnikoff NP; Kostrzewa RM; Harston CT; Kastin AJ; Christensen CW
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):121-4. PubMed ID: 13411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of CNS dopamine receptors by peptides.
    Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Paulose CS; Mishra RK
    Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
    Blunt SB; Jenner P; Marsden CD
    Brain Res; 1992 Jun; 582(2):299-311. PubMed ID: 1393551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
    Ott MC; Costain WJ; Mishra RK; Johnson RL
    Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
    Mishra RK; Chiu S; Chiu P; Mishra CP
    Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
    [No Abstract]   [Full Text] [Related]  

  • 30. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
    Hefti F; Melamed E; Wurtman RJ
    Brain Res; 1980 Aug; 195(1):123-37. PubMed ID: 6105003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
    Case TC; Snider SR; Hruby VJ; Rockway T
    Life Sci; 1985 Jul; 36(26):2531-7. PubMed ID: 2861549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the oxytocin fragment prolyl-leucyl-glycinamide on sexual behavior in the rat.
    Gorzalka BB; Luck KA; Tanco SA
    Pharmacol Biochem Behav; 1991 Feb; 38(2):273-9. PubMed ID: 1676168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
    Barbeau A
    Lancet; 1975 Oct; 2(7937):683-4. PubMed ID: 52054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLG regulates hnRNP-L expression in the rat striatum and pre-frontal cortex: identification by ddPCR.
    Costain WJ; Mishra RK
    Peptides; 2003 Jan; 24(1):137-46. PubMed ID: 12576095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dopaminergic and cholinergic drugs. naloxone and l-prolyl-leucyl-glycinamide on LSD-induced catalepsy.
    Chiu S; Mishra RK
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Aug; 313(1):45-50. PubMed ID: 6111027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.
    Cenci MA; Kalén P; Mandel RJ; Wictorin K; Björklund A
    Neuroscience; 1992; 46(4):943-57. PubMed ID: 1347413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
    Leff SE; Rendahl KG; Spratt SK; Kang UJ; Mandel RJ
    Exp Neurol; 1998 Jun; 151(2):249-64. PubMed ID: 9628761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.